Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Primary Systemic Anaplastic Large Cell Lymphoma, ALK-Negative”

3 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 3 of 3 results

Not applicableLooking for participantsNCT05978141
What this trial is testing

A Registry for People With T-cell Lymphoma

Who this might be right for
T-cell LymphomaNK-Cell LymphomaT-cell Prolymphocytic Leukemia+28 more
Memorial Sloan Kettering Cancer Center 1,000
Testing effectiveness (Phase 2)Ended earlyNCT03075553
What this trial is testing

Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Who this might be right for
Blastic Plasmacytoid Dendritic Cell NeoplasmHepatosplenic T-Cell LymphomaHTLV-1 Infection+14 more
Mayo Clinic 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT02978625
What this trial is testing

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

Who this might be right for
Anaplastic Large Cell Lymphoma, ALK-NegativeAnaplastic Large Cell Lymphoma, ALK-PositiveApocrine Carcinoma+36 more
National Cancer Institute (NCI) 68